how prevalent are akt pathway alterations in breast cancer?
Published 6 months ago • 444 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
0:58
results of capitello291 - capivasertib
-
21:03
how to treat hr breast cancer with dr. virginia kaklamani | onc brothers
-
21:42
dr. hope rugo discusses capivasertib fda approval based on capitello-291 study
-
14:02
approval of capivasertib for pik3ca/akt1/pten–altered breast cancer: jason mouabbi and carlos doti
-
3:18
pi3k/akt pathway aberrations in mcrpc
-
1:00:07
pi3k/akt pathway inhibition for the treatment of metastatic castrate-resistant prostate cancer
-
46:29
oncogene additivity in the pi3k pathway in cancer
-
1:22
dr. o'shaughnessy on the utility of capivasertib in targeting akt in breast cancer
-
1:10
addressing the mechanism of action for the akt pathway in tnbc
-
1:00
dr. chandarlapaty on role of the pi3k pathway in breast cancer
-
0:59
dr. rugo on pi3k and mtor inhibitors for the treatment of breast cancer
-
1:31:55
sylvester comprehensive cancer center annual oncology update - june 2022
-
3:56
breast cancer pathway guidelines for practitioners
-
59:30
improved targeting of cancers withmutations in the pi3k/pten pathway
-
1:25
dr. jhaveri on results of taselisib in pik3ca-mutated metastatic solid tumors
-
1:27
deciphering the role of pi3k mutations in her2 breast cancer
-
1:00:07
pi3k/akt pathway inhibition for metastatic castrate-resistant prostate cancer
-
1:29
the pi3k/akt signaling pathway: a mediator of metastasis in colorectal cancer
-
1:39
dr. burris discusses targeting the mtor pathway